Company Information

Company Name *

Company Description *

One line description: KaloCyte is redefining future emergency treatment for victims of traumatic blood loss with its first-in-class product ErythroMer, a dried red blood cell substitute that is easily transported and rapidly administered for when perishable donor blood is unavailable. Business Summary: Our groundbreaking research is succeeding where others have tried and failed, serving an untapped $7 billion market and positioning the company for early stage acquisition. Building on the science of the last 4 decades, KaloCyte's team of world-renowned physicians, bio-engineers, and trauma experts are safely advancing the development of a lifesaving bio-inspired, dried artificial blood substitute. A significant advancement in blood substitute science, KaloCyte's ErythroMer is a first-in-class synthetic, universal red blood cellsubstitute that transports oxygen just like native blood cells. The KaloCyte approach will equip first responders - civilian and defense - with an option when blood is not available, by having 24/7 access to KaloCyte's dried red blood cell substitute; all that is needed is sterile water to safely and quickly reconstitute and administer ErythroMer.

Website

Industry Type

Industry Type BioTherapy Hematology Other Unassigned

Incoming Channel